![Marc Bjurlin, DO, MSc,](https://www.med.unc.edu/urology/wp-content/uploads/sites/637/2018/10/Bjurlin-600x600.jpg)
5 months ago
UNC Urology Participates in Cutting Edge Clinical Trial of Potential New “Combination Therapy” for Bladder Cancer
A multi-center Phase 3 clinical trial named “QUILT” is exploring a potential new treatment that involves administering BCG (Bacillus Calmette-Guerin) combined with an experimental drug known as N-803 (Nogapendekin alfa inbakicept), with the goal of providing a synergistic therapeutic effect to some Bladder Cancer patients.